Results 81 to 90 of about 1,661,640 (282)
Integrated design optimization research and development in an industrial environment [PDF]
An overview is given of a design optimization project that is in progress at the GE Research and Development Center for the past few years. The objective of this project is to develop a methodology and a software system for design automation and ...
German, Marjorie D. +2 more
core +1 more source
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Optimal planning method of design project based on risk assessment model with task option
Nihon Kikai Gakkai ronbunshu, 2017 The product design project includes many uncertainties. It causes risk that a project target cannot be accompolished within lead time. In order to flexibly handle the uncertainty and avoid the risk, adaptive planning that can switch easily to another ...
Yutaka NOMAGUCHI +3 more
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source
Forging with optimal back-pressure profile using sequential approximate optimization
Nihon Kikai Gakkai ronbunshu, 2014 This paper proposes a method for determining optimal back-pressure profile in forging using a sequential approximate optimization (SAO). In forging, it is important to minimize an unfilled area for improving the product quality. To achieve this objective,
Masato OKADA +7 more
doaj +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Engineering optimization by constrained differential evolution with nearest neighbor comparison
Vietnam Journal of Mechanics, 2016 It has been proposed to utilize nearest neighbor comparison to reduce the number of function evaluations in unconstrained optimization. The nearest neighbor comparison omits the function evaluation of a point when the comparison can be judged by its ...
Pham Hoang Anh
doaj +1 more source
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source